Citigroup’s Insight Molecular Diagnostics IMDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-815
| Closed | -$2.67K | – | 6100 |
|
|
2026
Q1 | $2.67K | Buy |
815
+814
| +81,400% | +$4.73K | ﹤0.01% | 5383 |
|
|
2025
Q4 | $8 | Buy |
+1
| New | +$6 | ﹤0.01% | 5827 |
|
|
2023
Q2 | – | Sell |
-7
| Closed | -$49 | – | 5683 |
|
|
2023
Q1 | $49 | Sell |
7
-45
| -87% | -$334 | ﹤0.01% | 5327 |
|
|
2022
Q4 | $309 | Buy |
52
+8
| +18% | +$88 | ﹤0.01% | 5560 |
|
|
2022
Q3 | $1K | Sell |
44
-132
| -75% | -$2.29K | ﹤0.01% | 5660 |
|
|
2022
Q2 | $3K | Sell |
176
-38
| -18% | -$864 | ﹤0.01% | 5787 |
|
|
2022
Q1 | $6K | Sell |
214
-700
| -77% | -$22.4K | ﹤0.01% | 5762 |
|
|
2021
Q4 | $39K | Buy |
914
+571
| +166% | +$32.8K | ﹤0.01% | 5187 |
|
|
2021
Q3 | $24K | Buy |
343
+149
| +77% | +$13.7K | ﹤0.01% | 5155 |
|
|
2021
Q2 | $22K | Sell |
194
-42
| -18% | -$4.1K | ﹤0.01% | 5250 |
|
|
2021
Q1 | $24K | Sell |
236
-353
| -60% | -$33.5K | ﹤0.01% | 5145 |
|
|
2020
Q4 | $28K | Buy |
589
+438
| +290% | +$16.1K | ﹤0.01% | 6441 |
|
|
2020
Q3 | $4K | Sell |
151
-140
| -48% | -$4.01K | ﹤0.01% | 7134 |
|
|
2020
Q2 | $11K | Sell |
291
-8
| -3% | -$413 | ﹤0.01% | 7008 |
|
|
2020
Q1 | $15K | Buy |
299
+81
| +37% | +$3.97K | ﹤0.01% | 6862 |
|
|
2019
Q4 | $10K | Buy |
218
+165
| +311% | +$5.95K | ﹤0.01% | 7205 |
|
|
2019
Q3 | $2K | Sell |
53
-266
| -83% | -$10.5K | ﹤0.01% | 7546 |
|
|
2019
Q2 | $16K | Sell |
319
-719
| -69% | -$59.8K | ﹤0.01% | 7162 |
|
|
2019
Q1 | $82K | Buy |
+1,038
| New | +$66.9K | ﹤0.01% | 5934 |
|
|
2018
Q2 | – | Sell |
-2
| Closed | – | – | 7690 |
|
|
2018
Q1 | $0 | Sell |
2
-1
| -33% | -$66 | ﹤0.01% | 7630 |
|
|
2017
Q4 | $0 | Buy |
+3
| New | +$338 | ﹤0.01% | 7622 |
|
|
2017
Q3 | – | Sell |
-494
| Closed | -$51K | – | 7383 |
|
|
2017
Q2 | $51K | Buy |
+494
| New | +$56.2K | ﹤0.01% | 5778 |
|
|
2016
Q4 | – | Sell |
-2
| Closed | – | – | 7281 |
|
|
2016
Q3 | $0 | Buy |
+2
| New | +$161 | ﹤0.01% | 7146 |
|
|
2016
Q2 | – | Sell |
-138
| Closed | -$13K | – | 7312 |
|
|
2016
Q1 | $13K | Buy |
+138
| New | +$12.2K | ﹤0.01% | 6728 |
|
Other funds holding IMDX
BC
AIC
PVI
FOR
FIA
Citigroup's IMDX Position: Q2 2026 in Review
Citigroup sold out of Insight Molecular Diagnostics (IMDX) in Q2 2026, closing a stake of 815 shares — an estimated $2.67K sold.
Citigroup first reported a position in IMDX in Q1 2016 and held it in 24 quarters. The position peaked at $82K in Q1 2019. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.
- Citigroup reported no remaining Insight Molecular Diagnostics position as of Q2 2026 after selling out during the quarter.
- Citigroup sold 815 Insight Molecular Diagnostics shares in Q2 2026, an estimated $2.67K.
- Citigroup first reported a position in Insight Molecular Diagnostics in Q1 2016 and held it in 24 quarters.
- Citigroup's Insight Molecular Diagnostics position peaked at $82K in Q1 2019.
- 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.